Kamada (KMDA) Cash from Financing Activities (2013 - 2026)
Kamada (KMDA) posted quarterly Cash from Financing Activities of -$856000.0 for Q1 2026, down 192.15% year-on-year from $928918.5 in Q1 2025, and up 27.4% on a QoQ basis from -$1.2 million in Q4 2025.
Kamada (KMDA) Cash from Financing Activities (2013 - 2026) Analysis & Trends
Kamada (KMDA) has reported Cash from Financing Activities for 14 consecutive years, with -$856000.0 the latest figure, recorded in Q1 2026.
- Quarterly Cash from Financing Activities fell 192.15% year-over-year to -$856000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$18.9 million (down 123.37% YoY) and the FY2025 annual result came in at -$18.3 million, down 31.87% from the prior year.
- Cash from Financing Activities climbed to -$856000.0 in Q1 2026 per KMDA's latest filing, from -$1.2 million in the prior quarter.
- Over the last five years, Cash from Financing Activities for KMDA reached as high as $31.3 million in Q3 2023 and fell as low as -$16.1 million in Q2 2025.
- A 5-year average of -$961184.8 and a median of -$1.6 million in 2023 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities surged 1384222.07% — and 2024, when it slumped 199101.67%.
- Year by year, Cash from Financing Activities stood at -$2.9 million in 2022, then surged by 44.93% to -$1.6 million in 2023, then surged by 55.22% to -$708000.0 in 2024, then slumped by 66.53% to -$1.2 million in 2025, then rose by 27.4% to -$856000.0 in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered -$856000.0, -$1.2 million, and -$754000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -840.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -494.13 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -1.48 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -203.80 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -86.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -65.00 Mn |
| 10 | Kamada | 401.22 Mn | 328.07 Mn | 19.12 Mn | -856,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -856,000.00 |
| Mar 31, 2026 | -856,000.00 |
| Dec 31, 2025 | -1.18 Mn |
| Dec 31, 2025 | -1.18 Mn |
| Sep 30, 2025 | -754,000.00 |
| Sep 30, 2025 | -754,000.00 |
| Jun 30, 2025 | -16.12 Mn |
| Jun 30, 2025 | -16.12 Mn |
| Mar 31, 2025 | -293,000.00 |
| Mar 31, 2025 | -293,000.00 |
| Dec 31, 2024 | -708,000.00 |
| Dec 31, 2024 | -708,000.00 |
| Sep 30, 2024 | -4.79 Mn |
| Sep 30, 2024 | -4.79 Mn |
| Jun 30, 2024 | -2.68 Mn |
| Jun 30, 2024 | -2.68 Mn |
| Mar 31, 2024 | -5.74 Mn |
| Mar 31, 2024 | -5.74 Mn |
| Dec 31, 2023 | -1.58 Mn |
| Dec 31, 2023 | -1.58 Mn |